Intraprostatic Tumor Segmentation on PSMA PET Images in Patients with Primary Prostate Cancer with a Convolutional Neural Network.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
PMID:

Abstract

Accurate delineation of the intraprostatic gross tumor volume (GTV) is a prerequisite for treatment approaches in patients with primary prostate cancer (PCa). Prostate-specific membrane antigen PET (PSMA PET) may outperform MRI in GTV detection. However, visual GTV delineation underlies interobserver heterogeneity and is time consuming. The aim of this study was to develop a convolutional neural network (CNN) for automated segmentation of intraprostatic tumor (GTV-CNN) in PSMA PET. The CNN (3D U-Net) was trained on the Ga-PSMA PET images of 152 patients from 2 different institutions, and the training labels were generated manually using a validated technique. The CNN was tested on 2 independent internal (cohort 1: Ga-PSMA PET, = 18 and cohort 2: F-PSMA PET, = 19) and 1 external (cohort 3: Ga-PSMA PET, = 20) test datasets. Accordance between manual contours and GTV-CNN was assessed with the Dice-Sørensen coefficient (DSC). Sensitivity and specificity were calculated for the 2 internal test datasets (cohort 1: = 18, cohort 2: = 11) using whole-mount histology. The median DSCs for cohorts 1-3 were 0.84 (range: 0.32-0.95), 0.81 (range: 0.28-0.93), and 0.83 (range: 0.32-0.93), respectively. Sensitivities and specificities for the GTV-CNN were comparable with manual expert contours: 0.98 and 0.76 (cohort 1) and 1 and 0.57 (cohort 2), respectively. Computation time was around 6 s for a standard dataset. The application of a CNN for automated contouring of intraprostatic GTV in Ga-PSMA and F-PSMA PET images resulted in a high concordance with expert contours and in high sensitivities and specificities in comparison with histology as a reference. This robust, accurate and fast technique may be implemented for treatment concepts in primary prostate cancer. The trained model and the study's source code are available in an open source repository.

Authors

  • Dejan Kostyszyn
    Division of Medical Physics, Department of Radiation Oncology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Tobias Fechter
    Division of Medical Physics, Department of Radiation Oncology, Medical Center, Faculty of Medicine, University of Freiburg, German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Nico Bartl
    German Cancer Consortium (DKTK), Partner Site Freiburg, Germany.
  • Anca L Grosu
    German Cancer Consortium (DKTK), Partner Site Freiburg, Germany.
  • Christian Gratzke
    Department of Urology, LMU Munich, Munich, Germany. Electronic address: christian.gratzke@med.uni-muenchen.de.
  • August Sigle
    Department of Urology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Michael Mix
    Department of Nuclear Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Juri Ruf
    Department of Nuclear Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Thomas F Fassbender
    Department of Nuclear Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Selina Kiefer
    Institute for Surgical Pathology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Alisa S Bettermann
    Department of Radiation Oncology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Nils H Nicolay
    German Cancer Consortium (DKTK), Partner Site Freiburg, Germany.
  • Simon Spohn
    German Cancer Consortium (DKTK), Partner Site Freiburg, Germany.
  • Maria U Kramer
    Department of Radiation Oncology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Peter Bronsert
    Tumorbank Comprehensive Cancer Center Freiburg and Center for Surgical Pathology, Medical Center - University of Freiburg, Faculty of Medicine, Breisacher Straße 115a, Freiburg i. Br., 79106, Germany.
  • Hongqian Guo
    Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Institute of Urology, Nanjing University, No. 321 Zhongshan Rd, Nanjing, 210008, Jiangsu Province, China. dr.ghq@nju.edu.cn.
  • Xuefeng Qiu
    Department of Urology, Medical School of Nanjing University, Affiliated Drum Tower Hospital, Nanjing, China.
  • Feng Wang
    Department of Oncology, Binzhou Medical University Hospital, Binzhou, Shandong, China.
  • Christoph Henkenberens
    Department of Radiation Oncology, Hannover Medical School, Hannover, Germany.
  • Rudolf A Werner
    Department of Nuclear Medicine, Hannover Medical School, Hannover, Germany.
  • Dimos Baltas
    Division of Medical Physics, Department of Radiation Oncology, Medical Center, Faculty of Medicine, University of Freiburg, German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Philipp T Meyer
    Department of Nuclear Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Thorsten Derlin
    Department of Nuclear Medicine, Hannover Medical School, Hannover, Germany.
  • Mengxia Chen
    Department of Urology, Medical School of Nanjing University, Affiliated Drum Tower Hospital, Nanjing, China.
  • Constantinos Zamboglou
    German Cancer Consortium (DKTK), Partner Site Freiburg, Germany constantinos.zamboglou@uniklinik-freiburg.de.